SIX1/EYA1 are novel liver damage biomarkers in chronic hepatitis B and other liver diseases

Background: This study aimed to investigate the clinicopathological significance of sine oculis homeobox homolog 1 (SIX1) and eyes absent 1 (EYA1) in patients with chronic hepatitis B (CHB) and other liver diseases. Methods: SIX1 and EYA1 levels were detected in human serum and liver tissues by enzyme linked immunosorbent assay (ELISA) and immunofluorescent staining method, respectively. Results: The serum SIX1 and EYA1 levels in 313 CHB patients were 7.24 +/- 0.11 and 25.21 +/- 0.51 ng/mL, respectively, and these values were significantly higher than those in 33 healthy controls (2.84 +/- 0.15 and 13.11 +/- 1.01 ng/mL, respectively; P<0.05). Serum SIX1 and EYA1 levels were also markedly increased in patients with numerous other liver diseases, including liver fibrosis, hepatocellular carcinoma, fatty liver disease, alcoholic liver disease, fulminant hepatic failure, autoimmune liver disease, and hepatitis C, compared to the healthy controls (P<0.05). Dynamic observation of these proteins over time in 35 selected CHB patients revealed that SIX1 and EYA1 serum levels increased over an interval. Immunofluorescent staining revealed that both SIX1 and EYA1 were only expressed in hepatic stellate cells (HSCs), and their increased expression was evident in CHB liver tissue. Conclusions: SIX1 and EYA1 are novel biomarkers of liver damage in patients of CHB and other liver diseases, with potential clinical utility. Keywords: Sine oculis homeobox homolog 1 (SIX1); eyes absent 1 (EYA1); liver damage; chronic hepatitis B Background: This study aimed to investigate the clinicopathological significance of sine oculis homeobox homolog 1 (SIX1) and eyes absent 1 (EYA1) in patients with chronic hepatitis B (CHB) and other liver diseases. Methods: SIX1 and EYA1 levels were detected in human serum and liver tissues by enzyme linked immunosorbent assay (ELISA) and immunofluorescent staining method, respectively. Results: The serum SIX1 and EYA1 levels in 313 CHB patients were 7.24 +/- 0.11 and 25.21 +/- 0.51 ng/mL, respectively, and these values were significantly higher than those in 33 healthy controls (2.84 +/- 0.15 and 13.11 +/- 1.01 ng/mL, respectively; P<0.05). Serum SIX1 and EYA1 levels were also markedly increased in patients with numerous other liver diseases, including liver fibrosis, hepatocellular carcinoma, fatty liver disease, alcoholic liver disease, fulminant hepatic failure, autoimmune liver disease, and hepatitis C, compared to the healthy controls (P<0.05). Dynamic observation of these proteins over time in 35 selected CHB patients revealed that SIX1 and EYA1 serum levels increased over an interval. Immunofluorescent staining revealed that both SIX1 and EYA1 were only expressed in hepatic stellate cells (HSCs), and their increased expression was evident in CHB liver tissue. Conclusions: SIX1 and EYA1 are novel biomarkers of liver damage in patients of CHB and other liver diseases, with potential clinical utility.

Automated summary

This study revealed that the expression levels of SIX1 and EYA1 were significantly increased in patients with CHB and other liver diseases, suggesting their potential as novel biomarkers for liver damage, which could have clinical utility.